Aldeyra reported a significant reduction in net loss for Q2 2025 as it curtailed research and administrative costs, maintaining a healthy cash position despite continued development-stage losses.

Aldeyra Therapeutics, Inc. experienced a net loss of $9.9 million in the first quarter of 2025, an increase from $8.1 million in Q1 2024. This was primarily driven by a rise in research and development expenses, partially offset by a decrease in general and administrative costs. The company's cash and cash equivalents stood at $50.35 million.

Aldeyra Therapeutics, Inc. reported a net loss of $55.9 million for the fiscal year ended December 31, 2024, an increase from $37.5 million in the previous year. The company's research and development expenses significantly increased, primarily due to higher external clinical development and drug product manufacturing costs. The company continues to operate at a loss and anticipates needing additional financing to fund its operations and product development.

Aldeyra Therapeutics reported a net loss of $15.6 million, or $0.27 per share, for the first quarter of 2023. The company's cash and cash equivalents totaled $165.0 million as of March 31, 2023.

Aldeyra Therapeutics reported its full-year 2022 financial results, highlighting the Priority Review Designation for ADX-2191 and the NDA review for Reproxalap. The company's cash, cash equivalents, and marketable securities totaled $174.3 million as of December 31, 2022, expected to fund operations into the second half of 2024.

Aldeyra Therapeutics reported a net loss of $14.6 million for the third quarter of 2022, with cash, cash equivalents, and marketable securities exceeding $185.3 million as of September 30, 2022. The company is progressing with NDA submissions for reproxalap and ADX-2191 and advancing its pipeline of therapies for immune-mediated diseases.

Aldeyra Therapeutics reported a net loss of $17.8 million for the three months ended June 30, 2022. The company's cash, cash equivalents, and marketable securities totaled $196.7 million as of June 30, 2022.

Aldeyra Therapeutics reported a net loss of $16.8 million, or $0.29 per share, for the first quarter of 2022. Cash, cash equivalents, and marketable securities totaled $216.9 million as of March 31, 2022. The company believes existing funds will be sufficient to fund operations through the end of 2023.

Aldeyra Therapeutics reported full-year 2021 financial results, with cash and cash equivalents of $229.8 million as of December 31, 2021. The company believes that existing cash will be sufficient to fund operating expenses through the end of 2023. Net loss for the year was $57.8 million, or $1.07 per share.

Aldeyra Therapeutics reported a net loss of $15.8 million for the quarter ended September 30, 2021, compared to a net loss of $8.9 million for the same period in 2020. The company's cash and cash equivalents were $241.4 million as of September 30, 2021, which is projected to fund operating expenses through 2023.

Aldeyra Therapeutics reported a net loss of $14.9 million for the quarter ended June 30, 2021, compared to a net loss of $7.5 million for the same period in 2020. As of June 30, 2021, cash and cash equivalents totaled $249.7 million.

Aldeyra Therapeutics reported a net loss of $11.3 million for the quarter ended March 31, 2021, compared to a net loss of $9.9 million for the same period in 2020. The company's cash and cash equivalents were $138.4 million as of March 31, 2021.

Aldeyra Therapeutics reported a net loss of $37.6 million for the full year 2020. The company's cash and cash equivalents were $77.9 million as of December 31, 2020, expected to fund operations through 2023.

Aldeyra Therapeutics reported a net loss of $8.9 million for Q3 2020, compared to a net loss of $18.7 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $86.2 million as of September 30, 2020, which is expected to fund operations through 2022.

Aldeyra Therapeutics reported a net loss of $7.5 million for the quarter ended June 30, 2020, compared to a net loss of $13.3 million for the same period in 2019. The company is advancing clinical-stage programs focused on the development of reproxalap and ADX-629. They expect to fund operations through 2022, including potential approvals for reproxalap in dry eye disease and allergic conjunctivitis.

Aldeyra Therapeutics reported a net loss of $9.9 million for the first quarter of 2020, compared to a net loss of $15.6 million for the same period in 2019. The company is advancing its pipeline with new clinical trials in systemic inflammatory diseases and updates on ocular disease programs, while extending its cash runway into 2022.

Aldeyra Therapeutics reported a net loss of $60.8 million for the year ended December 31, 2019. The company is strategically prioritizing late-stage ocular disease programs and expects to extend its cash runway through the end of 2021.